menu
    • menu
    [{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pegylated Interferon Alpha-2b","moa":"INF alpha receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"PharmaJet","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zydus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Zydus Pharmaceuticals \/ Zydus","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Pharmaceuticals \/ Zydus"},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zydus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Dermatology","graph2":"Approved","graph3":"Zydus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zydus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved","graph3":"Zydus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zydus Pharmaceuticals \/ Zydus","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Pharmaceuticals \/ Zydus"}]

    Find Clinical Drug Pipeline Developments & Deals by Zydus Pharmaceuticals

    Menu

    Zydus Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Recipient : Pharmacosmos AS

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Zydus Buys Rights from Pharmacosmos to Sell Drug to Treat Anemia in India, Nepal

                            Details : MonoFerric injection having Ferric derisomaltose, is a rapid, single dose intravenous therapy used for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used.

                            Brand Name : MonoFerric

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 09, 2022

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Recipient : Pharmacosmos AS

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zydus Receives Final Approval From USFDA for type 2 Diabetes Tablets

                            Details : Empagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally).

                            Brand Name : Empagliflozin-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 04, 2022

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zydus Gets USFDA Nod for Ivermectin Cream

                            Details : Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.

                            Brand Name : Ivermectin-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 04, 2022

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZyCoV-D

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : PharmaJet

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaJet Presents Partner Data Demonstrating Superior Immunogenicity With Their Needle-free Systems at World ...

                            Details : Phase 3 interim clinical trial data of their plasmid DNA vaccine ZyCoV-D, highlights the overall effectiveness and protective efficacy against COVID-19 in expanded age groups when administered intradermally with the Tropis® intradermal System.

                            Brand Name : ZyCoV-D

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 27, 2022

                            Lead Product(s) : ZyCoV-D

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : PharmaJet

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegylated Interferon Alpha-2b

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cadila Healthcare's Hepatitis C Drug Gets Approval for Emergency Use

                            Details : About 91 per cent of patients treated with the Pegylated Interferon Alpha-2b, tested negative for Covid-19 in standard RT-PCR tests by day seven, compared to nearly 79 per cent who were given the standard of care, the company said earlier this month.

                            Brand Name : PegiHep

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 23, 2021

                            Lead Product(s) : Pegylated Interferon Alpha-2b

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth